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verexpression of phosphatidylinositol phosphate
 
5-kinase (PIP5KI) isoforms 
 
 
 
, 
 
 
 
, or 
 
 
 
 in CV-1 cells
increased phosphatidylinositol 4,5-bisphosphate
(PIP2) levels by 35, 180, and 0%, respectively. Endocytosis of
transferrin receptors, association of AP-2 proteins with mem-
branes, and the number of clathrin-coated pits at the plasma
membrane increased when PIP2 increased. When expression
of PIP5KI
 
 
 
 was inhibited with small interference RNA in HeLa
cells, expression of PIP5KI
 
 
 
 was also reduced slightly, but
O
 
PIP5KI
 
 
 
 expression was increased. PIP2 levels and internal-
ization of transferrin receptors dropped 50% in these cells;
thus, PIP5KI
 
 
 
 could not compensate for loss of PIP5KI
 
 
 
.
When expression of PIP5KI
 
 
 
 was reduced, expression of
both PIP5KI
 
 
 
 and PIP5KI
 
 
 
 increased and PIP2 levels did not
change. A similar increase of PIP5KI
 
 
 
 and PIP5KI
 
 
 
 occurred
when PIP5KI
 
 
 
 was inhibited. These results indicate that con-
stitutive endocytosis in CV-1 and HeLa cells requires (and
may be regulated by) PIP2 produced primarily by PIP5KI
 
 
 
.
 
Introduction
 
Lipid components of membranes play an important role in
intracellular membrane traffic (Kobayashi et al., 1998;
Ktistakis, 1998; Roth, 1999; Cockcroft and De Matteis, 2001;
Cremona and De Camilli, 2001; Martin, 2001; Simonsen et
al., 2001). Mutations that block secretion or endocytosis
map to enzymes that modify lipids, particularly phosphati-
dylinositides, and many proteins that are important for vesicle
formation and consumption contain modules that bind to
specific lipids. In the process of endocytosis, many proteins
important for assembling a clathrin-coated vesicle bind to
phosphatidylinositol 4,5-bisphosphate (PIP2). These proteins
include the AP-2 adaptor responsible for binding endocytic
cargo (Gaidarov and Keen, 1999; Rohde et al., 2002), a brain-
specific adaptor protein (AP180; Ford et al., 2001), epsin,
which recruits clathrin and curves membranes (Ford et al.,
2002), and dynamin, a GTPase that functions in the transfor-
mation of a clathrin-coated bud into a vesicle (Lin et al., 1997;
Achiriloaie et al., 1999; Vallis et al., 1999). Reagents that
sequester PIP2 inhibit clathrin-mediated endocytosis in vitro
(Jost et al., 1998), and mutant epsin (Itoh et al., 2001) or AP-2
mu2 (Rohde et al., 2002) unable to bind PIP2 are dominant
inhibitors of endocytosis. Clathrin coats also contain a phos-
phatidylinositol 5-phosphatase, synaptojanin (McPherson et
al., 1996), and nerve terminals in mice lacking synaptojanin
appear to have defects in the uncoating of clathrin-coated
vesicles (Cremona et al., 1999). Similarly, mutants of 
 
Cae-
norhabditis elegans
 
 with defects in synaptojanin have defects in
both the budding and uncoating of clathrin-coated vesicles
(Harris et al., 2000). Thus, PIP2 appears to regulate the assem-
bly and disassembly of a clathrin coat.
PIP2 might function for clathrin-mediated endocytosis in
several ways. PIP2 might serve as a membrane identity
marker, allowing proteins important for endocytosis to collect
at the correct membrane surface. In this event, PIP2 might
control where endocytosis occurs without influencing the
rates of endocytosis, if the steady-state concentration of
PIP2 at the plasma membrane supports maximum rates of
endocytosis. PIP2, either directly or after phosphorylation to
PIP3 (Gaidarov et al., 1996, 2001; Rapoport et al., 1997),
might also act as an allosteric regulator of proteins important
for endocytosis, and thus modulate the endocytic rate. Phos-
phatidylinositides including PIP2 increase the affinity of
AP-2 proteins for the internalization signals in endocytic
cargo (Rapoport et al., 1997), and the crystal structure of the
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AP-2 tetramer suggests that binding to phosphoinositides
may be required to open the binding site for internalization
signals (Collins et al., 2002).
In addition to proteins of the clathrin coat, many other
proteins bind PIP2 at the plasma membrane, and there must
exist some mechanism regulating competition between dif-
ferent processes. One way to accomplish this would be to in-
crease the production of PIP2 locally by controlling the loca-
tion and activity of a phosphatidylinositol phosphate kinase.
Interactions between the kinase and components of a partic-
ular cellular function that is regulated by PIP2 would then
serve to channel PIP2 into the pathway subserving that
function.
Two classes of lipid kinases produce PIP2 (Fruman et al.,
1998). Originally classified as PI4P5K type I and type II,
type I enzymes were found to phosphorylate the 5 position
of the abundant phosphatidylinositol 4-phosphate to pro-
duce PIP2, but type II enzymes are really PIP 4-kinases that
produce PIP2 by phosphorylating the 4 position of phos-
phatidylinositol 5-phosphate, a lipid species about which lit-
tle is currently known. There are three isoforms of type I en-
zymes; phosphatidylinositol phosphate 5-kinase (PIP5KI) 
 
 
 
,
 
 
 
, and 
 
 
 
. The mouse and human PIP5KI
 
 
 
 and 
 
 
 
 enzymes
were named in a reciprocal manner (Ishihara et al., 1996;
Loijens and Anderson, 1996), and in this report we will use
the human nomenclature throughout. PIP5KI enzymes con-
tain a highly conserved central catalytic domain of 
 
 
 
400
residues and have nonconserved amino- and carboxyl-termi-
nal sequences. The terminal domains contain information
for dimerization of the enzyme (Galiano et al., 2002), and
may serve other isoform-specific functions. PIP5KI enzymes
and their yeast counterpart are negatively regulated by phos-
phorylation (Vancurova et al., 1999; Park et al., 2001). Two
splice variants of PIP5KI
 
 
 
 are produced, and the longer
form, which predominates in brain, is found at adhesion
plaques as well as at the plasma membrane (Di Paolo et al.,
2002; Ling et al., 2002). PIP5KI
 
 
 
 and 
 
 
 
 have been impli-
cated in different specialized forms of endocytosis. PIP5KI
 
 
 
is the major producer of PIP2 at the synapse, a site of ex-
tremely active endocytosis (Wenk et al., 2001). A truncated
form of PIP5KI
 
 
 
 was identified through a genetic screen for
cDNAs that could restore signaling through a mutant CSF-1
receptor (Davis et al., 1997). The truncated kinase appar-
ently acted as a dominant-negative inhibitor of endocytosis,
allowing the mutant receptor to persist at the plasma mem-
brane. Overexpressed PIP5KI
 
 
 
 increased endocytosis of ac-
tivated EGF receptors and was coprecipitated with the re-
ceptors, whereas PIP5KI
 
 
 
 was reported to have no effect on
endocytosis of EGF (Barbieri et al., 2001). These observa-
tions are consistent with the ability of PIP5KI enzymes to
regulate clathrin coat formation for at least certain endocytic
events, and suggest that different isoforms may function in
different cell types or for different endocytic activities.
Both endocytosis at the synapse and regulated endocytosis
of growth factor receptors differ in a number of ways from the
constitutive endocytosis of nutrient receptors, such as the
transferrin receptor. Both use additional components com-
pared with constitutive endocytosis. Endocytosis of synaptic
vesicle components is an order of magnitude faster than clath-
rin-mediated endocytosis in other cell types, and the rate of
endocytosis of growth factor and hormone receptors is acutely
regulated. Thus, we were interested in determining if the rates
of constitutive endocytosis might be regulated by PIP2 levels,
and if so, by which enzyme. Using overexpression and RNAi
to raise or lower the cellular concentration of each of the
PIP5KI isoforms in HeLa or CV-1 cells, we found that in-
creased PIP2 levels increased the rate of constitutive endocy-
tosis. PIP5KI
 
 
 
 was the major contributor to PIP2 levels and
to clathrin-mediated endocytosis of the transferrin receptor.
In contrast, increased expression of exogenous PIP5KI
 
 
 
 or in-
creased transcription of endogenous PIP5KI
 
 
 
 had no impact
on endocytosis or cellular PIP2 levels.
Figure 1. PIP5KI is effectively overexpressed by recombinant 
adenoviruses or transfection. (A) CV1 cells infected with adenovirus 
expressing PIP5KI  or   or transfected with plasmids expressing either 
the long (l) or short (s) forms of PIP5KI  were labeled with antibodies 
for HA or myc tags as indicated. The overexpressed isoforms all 
localized at the plasma membrane. (B) Cells treated as in A were 
32P-labeled (4 h) and their lipids were extracted. Equal counts of 
lipids were resolved by TLC, and the bottom spot corresponding to 
PIP2 was quantified by densitometry. An example of the image of a 
TLC plate showing samples from uninfected cells (C) and two samples 
expressing PIP5KI  (I ) is shown. (C) Averages of PIP2 levels in 
three or more samples of cells expressing each of the three PIP5KI 
isoforms are graphed relative to the control (C   100) with SD.T
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Results
 
The effects of increased expression of PIP5KI enzymes 
on internalization of transferrin receptors
 
To increase the expression of PIP5KI isoforms, CV-1 cells
were infected with replication-defective adenoviruses ex-
pressing PIP5KI
 
 
 
 or 
 
 
 
, or were transiently transfected with
plasmid vectors to express the 87- or 90-kD variants of the 
 
 
 
isoform. Cells were stained with antibodies to the epitope
tags on the recombinant proteins to determine the percent-
age of cells expressing them and the locations of the proteins
within the cells. PIP5KI isoforms were effectively overex-
pressed after either adenoviral infection (
 
 
 
85% efficiency)
or transient transfection (
 
 
 
20% efficiency). All three over-
expressed isoforms located primarily at the plasma mem-
brane (Fig. 1 A). To circumvent the low efficiency of trans-
fection of the plasmid expressing PIP5KI
 
 
 
 and to be able to
perform biochemical experiments, we cotransfected the
PIP5KI
 
 
 
 expression plasmid with a GFP expression plasmid
at a 3 to 1 ratio, and determined that 97% of cells expressing
GFP also expressed PIP5KI
 
 
 
 by fluorescence microscopy.
Then, we sorted the GFP-positive cells by flow cytometry
one day after transfection and performed biochemical exper-
iments on the sorted cells one day after they were returned
to culture.
After infection or transfection, cells were labeled with
[
 
32
 
P]orthophosphate, and lipids were extracted and analyzed
by TLC (Fig. 1 B). The three isoforms of PIP5KI increased
PIP2 production to different extents. Overexpression of
PIP5KI
 
 
 
 and 
 
 
 
 resulted in about a 35 and 180% increase in
PIP2 (Fig. 1 C), respectively, and 
 
 
 
 had no effect. However,
the PIP5KI
 
 
 
 expression vector that we used did cause the
formation of actin comets when transfected into REF52
cells (unpublished data). Actin comets are produced in
REF52 cells transfected with PIP5KI
 
 
 
 or 
 
 
 
 (Rozelle et al.,
2000); thus, the PIP5KI
 
 
 
 produced by our vectors was ac-
tive in other cellular backgrounds.
Internalization assays were performed to determine
whether PIP5KI expression levels would affect constitutive
endocytosis. The expression of transferrin receptors in cells
expressing PIP5KI proteins was examined by immunoblot-
ting (unpublished data) and by fluorescence microscopy
(Fig. 2 A), and was not changed compared with control
cells, although the cells overexpressing PIP5KI
 
 
 
 became
more elongated than uninfected cells. Overexpression of ei-
ther the 87-kD (unpublished data) or 90-kD 
 
 
 
 isoforms had
no effect on endocytosis of transferrin receptors, but overex-
pression of PIP5KI
 
 
 
 and 
 
 
 
 increased the rate of endocytosis
of transferrin 
 
 
 
30 and 100%, respectively (Fig. 2). To de-
termine whether the observed differences between the 
 
 
 
 and
 
 
 
 isoforms were due to differences in protein expression lev-
els, we immunoprecipitated the overexpressed proteins from
lysates of cells 
 
35
 
S-labeled with amino acids. We found that
both proteins were expressed at a very similar level (unpub-
lished data).
 
Expression of PIP5KI
 
 
 
 increases internalization of 
influenza virus hemagglutinin (HA) Y543
 
To determine if increased expression of PIP5KI
 
 
 
 stimulated
constitutive endocytosis in general, we measured internaliza-
tion of a second protein, the HA Y543 mutant. This HA
contains a cysteine-to-tyrosine mutation in a very short (10
amino acid) cytoplasmic domain that allows HA Y543 to be
internalized by clathrin-coated pits (Lazarovits and Roth,
1988). When compared with cells infected with a GFP ade-
novirus, cells infected with a PIP5KI
 
 
 
 adenovirus had in-
creased internalization of HA Y543 similar to the increased
rate observed for the transferrin receptor (Fig. 3). Thus, the
effect of increased expression of PIP5KI
 
 
 
 on endocytosis is
not specific for a particular receptor.
 
Drugs that disrupt the actin cytoskeleton do not 
antagonize transferrin uptake in cells 
overexpressing PIP5KI
 
Because PIP5KI has been reported to stimulate formation
of actin stress fibers and affect cell shape (Yamamoto et al.,
2001), we investigated the possibility that the increase in
endocytosis could be a consequence of changes in the orga-
nization of the actin cytoskeleton. We tested the effect of
two toxins, cytochalasin D and latrunculin A, on transferrin
uptake in both control cells and in cells overexpressing
PIP5KI
 
 
 
. Both of these toxins result in actin filament disas-
sembly; cytochalasin D by capping actin filaments and la-
trunculin A by sequestering actin monomers (Coue et al.,
Figure 2. Transferrin internalization is increased in cells 
overexpressing PIP5KI  or  , but not  . (A) Uninfected or CV-1 
cells infected with adenovirus expressing PIP5KI  were allowed to 
bind fluorescent transferrin. Images of the cells were taken with a 
confocal microscope (model 510; Carl Zeiss MicroImaging, Inc.) at 
identical settings. Infected and uninfected cells bound similar amounts 
of transferrin. (B) Transferrin endocytosis was measured in cells with 
overexpressed PIP5KI isoforms as described in Materials and methods. 
Averages of three independent experiments with SD are shown, 
except in the bottom panel, in which a representative experiment of 
two is shown.T
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1987; Sampath and Pollard, 1991). Overexpression of
PIP5KI
 
 
 
 resulted in increased endocytosis to the same ex-
tent either in the presence or absence of cytochalasin D
(Fig. 4) or latrunculin A (unpublished data). Thus, the in-
crease in endocytosis caused by overexpression of PIP5KI
 
 
 
was not related to the previously described increase in stress
fibers (Yamamoto et al., 2001).
 
Overexpression of PIP5KI increases the number of 
clathrin-coated pits and the proportion of 
membrane-associated AP-2
 
The ways in which transferrin uptake could be increased
would be to increase the density of transferrin receptors
packed into each coated pit, to increase the numbers of
coated pits that form, or to increase the speed with which
coated pits form and bud off. Thus, we examined how over-
expression of PIP5KI would affect the number of clathrin-
coated pits at the plasma membrane and the proportion of
AP-2 adaptor proteins that were bound to membranes.
Analysis by EM revealed that overexpression of PIP5KI
 
 
 
 or
 
 
 
 increased the number of clathrin-coated pits at the plasma
membrane by 0.7- and 1.7-fold, respectively (Table I). Im-
munoblots of cytosolic and membrane fractions from cells
overexpressing either isoform showed that the fraction of
 
 
 
-adaptin bound to membranes had increased (Fig. 5). To-
gether, these results show that the level of PIP2 in CV-1 cells
produced by endogenous PIP5KI enzymes under the growth
conditions of our experiments is rate limiting for endocyto-
sis, and thus the rates of constitutive endocytosis might be
regulated through production of PIP2.
 
Expression of PIP5KI proteins is coordinately regulated
 
To determine which of the PIP5KI isoforms is required for
constitutive endocytosis, expression of each was inhibited
by small interference RNA (siRNA) oligonucleotides in
HeLa cells. We observed that on the second day after trans-
fection with siRNA oligonucleotides specific for PIP5KI
 
 
 
,
cells appeared to be healthy, but their growth rate had
slowed. Therefore, the effects of siRNA on the steady-state
levels of protein of each of the three PIP5KI isoforms were
measured after two days by immunoblotting. A representa-
tive immunoblot from an experiment targeting PIP5KI
 
 
 
expression is shown in Fig. 6, with quantification of the av-
erages of three such experiments. Expression was reduced
by 75, 50, and 90% for the 
 
 
 
, 
 
 
 
, and 
 
 
 
 isoforms, respec-
tively. Only the siRNA specific for PIP5KI
 
 
 
 decreased
PIP2 production, and did so by 
 
 
 
50% (Fig. 6 B). How-
ever, when mRNA for each of the three PIP5KI isoforms
was measured in cells treated with siRNA for one of them,
we observed that there were changes in the expression of the
other two PIP5KI enzymes (Fig. 6 C). RNAi targeting
PIP5KI
 
 
 
 also slightly reduced PIP5KI
 
 
 
 and induced a
threefold increase in expression of PIP5KI
 
 
 
. Similar to the
overexpression experiments, this stimulation of mRNA for
endogenous PIP5KI
 
 
 
 did not result in an increase in total
PIP2 production (Fig. 6 B). The small decrease in PIP5KI
 
 
 
was caused by three different siRNA oligonucleotides spe-
cific for regions of PIP5KI
 
 
 
 that differed from PIP5KI 
(unpublished data). In contrast, siRNA specific for
PIP5KI  caused almost a twofold increase in mRNA for
both PIP5KI  and  . siRNA specific for PIP5KI  caused a
similar increase in mRNA for the other two isoforms. Mea-
sured by immunoblotting, changes in protein levels of the
other two isoforms in cells in which one was targeted by
Figure 3. Overexpression of PIP5KI  
increases the rate of internalization of 
HA Y543. CV1 cells were infected with 
adenovirus encoding PIP5KI  or GFP 
(control). After 24 h, both samples were 
infected with recombinant SV40 virus 
expressing HA Y543. 26 h after the SV40 
infections, the cells were 
35S-labeled with 
amino acids, and internalization of HA 
was measured for the indicated times as 
described in Materials and methods. A 
shows the results of a representative 
experiment and B shows the quantification 
of four experiments. Error bars in B are 
standard errors.
Figure 4. Cytochalasin D does not abolish the increased endocytosis 
observed in cells overexpressing PIP5KI . CV1 cells were infected 
with adenovirus expressing PIP5KI  as in Fig. 1. Before measuring 
endocytosis, cells were treated with 5  M cytochalasin D for 30 min. 
Cells were also stained with phalloidin to confirm that the actin 
cytoskeleton was disrupted (not depicted).
Table I. Overexpression of PIP5KI increases the number of 
clathrin-coated pits
Control PIP5KI  PIP5KI 
Exp 1 0.055 (34) 0.091 (24) 0.153 (52)
Exp 2 0.061 (23) 0.102 (35) 0.161 (43)
Cells infected with adenovirus-encoding  -galactosidase (Control) and
PIP5KI  and PIP5KI  were processed for EM. Clathrin-coated pits were
counted and expressed as coated pit/micrometer of plasma membrane (see
Materials and methods). Numbers in parenthesis represent number of
coated pits counted for each sample. Data from two experiments are
shown.T
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siRNA were less than the changes in mRNA, but the pat-
terns were similar (unpublished data). As is discussed in
more detail in the Discussion, these results indicate that
gene expression of each PIP5KI isoform is sensitive to the
expression of the other isoforms. However, the   isoform
does not compensate for loss of   or  , even when signifi-
cantly overexpressed.
Because of this unexpected result, we investigated the ef-
fect of overexpressing a single PIP5KI isoform on the expres-
sion of the other two isoforms by Western blot analysis (Fig.
7). Overexpressing PIP5KI  decreased PIP5KI  and   by
40%. Increased PIP5KI  reduced PIP5KI   30%, but had
no effect on PIP5KI . In contrast, overexpressing PIP5KI 
did not significantly change the expression levels of
PIP5KI  or  . Thus, both overexpression and knockdown
experiments indicate that the expression of the three PIP5KI
enzymes is interdependent, but the regulation is complex
and the three isoforms are obviously not equivalent.
A reduction in cellular PIP2 production decreases 
endocytosis of transferrin receptors
In cells treated with siRNA oligonucleotides that targeted
PIP5KI , transferrin internalization was reduced by 40%,
whereas siRNA specific for PIP5KI  or   did not have a sig-
nificant effect (Fig. 8 A). This result was consistent with the
reduction of PIP2 production in cells in which levels of
PIP5KI  were lowered, but no change was observed in PIP2
in cells in which the other isoforms were lowered. This effect
was not due to a general toxic effect of loss of PIP5KI , be-
cause under identical conditions, the rate of movement of
the influenza virus HA through the early secretory pathway
was not decreased (unpublished data). In the case of in-
creased PIP2 production in cells overexpressing PIP5KI ,
we observed a decrease in the ratio of cytosolic-to-mem-
brane-bound AP-2 adaptors (Fig. 5). In contrast, in cells
treated with siRNA in which expression of PIP5KI  as well
as PIP2 levels decreased, the ratio of cytosolic to membrane-
bound AP-2 increased twofold (Fig. 8 B). Thus, it is possible
that the decrease in the rate of endocytosis in cells in which
PIP2 is lowered is due, at least in part, to decreased associa-
tion of AP-2 with membranes.
Discussion
Three isoforms of type I PIP5K have been described;
PIP5KI ,  , and   (Ishihara et al., 1996, 1998; Loijens
and Anderson, 1996). PIP5KI , but not  , has been re-
ported to be required for endocytosis of the EGF receptor
(Barbieri et al., 2001) and to have effects on endosomes
(Galiano et al., 2002). PIP5KI  is the major producer of
Figure 5. Cells overexpressing PIP5KI  or   have more AP-2 on 
membranes. Cytosol (S100) and crude membrane fractions (P100; 
see Materials and methods) from cells overexpressing PIP5KI 
enzymes or  -galactosidase (C) were resolved by 10% SDS-PAGE, 
transferred to nitrocellulose membranes, and blotted with antibody 
specific for  -adaptin. An example of such a blot is shown. Averages 
from three independent experiments are graphed with SD.
Figure 6. Small interfering RNA specific for 
PIP5KI  (but not   or  ) reduces PIP2 levels in 
HeLa cells. HeLa cells were transfected with siRNA 
oligos targeting the  ,  , or   isoforms of PIP5KI or 
an irrelevant sequence (control, C). Western blots 
with antibodies specific for the respective protein 
and tubulin (loading control) were performed 48 h 
after transfection. (A) An example of a Western blot 
specific for PIP5KI  is shown. Similar blots were 
quantified by densitometry, and the values are 
presented graphically. (B) PIP2 levels in cultures 
transfected with siRNAs specific for the enzymes 
shown were measured as described in Fig. 1 B. 
(C) mRNA for each enzyme in cells treated with 
siRNA specific for one isoform were measured by 
real-time PCR. For each isoform, values in A and B 
are expressed as a percentage of the value measured 
in the control transfected with unrelated siRNA. 
All graphs present the averages of at least three 
experiments with SD.T
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PIP2 in the synapse (Wenk et al., 2001), where PIP2 is
required for the recycling of synaptic vesicle membranes
(Cremona et al., 1999). In contrast, we find that PIP5KI 
plays a major role in constitutive receptor-mediated en-
docytosis in CV-1 cells and HeLa cells. Our results show
that the rates of constitutive endocytosis can be both in-
creased and decreased by changes in PIP2 levels, which sug-
gests that constitutive endocytosis may be regulated through
changes in the activity or location of PIP5KI enzymes, and
perhaps other proteins that activate PIP5KI or that supply
its substrate, PI4P.
We observed that overexpression of recombinant
PIP5KI  (both splice variants) did not change PIP2 levels or
impact constitutive endocytosis, and the increase in endoge-
nous PIP5KI  that occurred when expression of PIP5KI 
was inhibited by siRNA did not compensate for the loss of
PIP5KI . Therefore, it is likely that PIP5KI  plays no role
in constitutive endocytosis in either CV-1 cells or HeLa
cells. Either this isoform is not active in these cell types, or it
acts in a location different from the plasma membrane that
does not provide a significant fraction of the total PIP2 pro-
duction in these cells. We can conclude less about PIP5KI .
Overexpressing this isoform had less impact on PIP2 levels
than did overexpressing PIP5KI , although protein levels of
PIP5KI  were slightly higher. A possibility consistent with
our observations and those reported by Barbieri et al. (2001)
is that a significant fraction of PIP5KI  may be sequestered
and not available for constitutive endocytosis, perhaps by as-
sociating with growth factor receptors. Perhaps this fraction
of PIP5KI  is not constitutively active, and only the remain-
ing PIP5KI  is able to produce PIP2 and impact constitu-
tive endocytosis. We cannot answer the question of whether
PIP5KI  plays some role in constitutive endocytosis or can
compensate for the loss of PIP5KI , because siRNA oligo-
nucleotides that inhibited PIP5KI  also lowered expres-
sion of PIP5KI . Three separate oligonucleotide sequences
of PIP5KI  that contained significant mismatches with
PIP5KI  each had this effect, and we currently have no ex-
planation for this.
Also, we observed that inhibiting the expression of one
isoform of PIP5KI with siRNA resulted in increased expres-
sion of the other isoforms and, conversely, overexpression of
one isoform can result in reduced expression of the other
isoforms. Thus, transcription of PIP5KI genes is coordi-
nately regulated in some fashion. In the case of siRNA abla-
tion of PIP5KI , which also slightly lowered PIP5KI ,
PIP5KI  mRNA increased threefold, but this did not trans-
late into an active enzyme capable of rescuing total cellular
PIP2 levels (Fig. 6). PIP2 levels did not decrease when
PIP5KI  expression was lowered by siRNA, presumably be-
cause the increased expression of PIP5KI  compensated for
the loss of  . Inhibition of expression of PIP5KI  also
Figure 7. Overexpression of a PIP5KI enzyme affects the expression 
of the other isoforms. (A) Cell lysates obtained from CV1 cells 
individually overexpressing each of the three isoforms of PIP5KI or 
GFP (control, C) were subjected to SDS-PAGE and immunoblotted 
with antibodies to the three isoforms of PIP5KI and to tubulin as an 
internal control. (B) Blots were quantified by densitometry, and the 
results are expressed as percentage of protein in experimental samples 
compared with the amount of each protein in the control sample.
Figure 8. Reduced expression of PIP5KI  (but not   or  ) reduces the rate of transferrin 
internalization. (A) The internalization of transferrin was measured in cells treated with 
siRNA specific for one of the three PIP5KI isoforms as described in Materials and methods. 
(B) Cytosol (S100) and crude membrane fractions (P100; see Materials and methods) from 
cells with reduced levels of PIP5K were resolved by SDS-PAGE and were Western blotted 
with antibody specific for  -adaptin. A representative blot showing duplicate samples treated 
with siRNA targeting PIP5KI  and densitometric analysis of four experiments are shown. Error 
bars indicate the SD.T
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caused a twofold increase in the other two isoforms. Because
we have no evidence that PIP5KI  is active in HeLa cells, ei-
ther there is a mechanism that senses the presence of PIP5KI
isoforms independently of their enzymatic activity, which
suggests that they might share common interaction partners,
or the sensing mechanism uses a PIP2 pool that is a small
fraction of total cellular PIP2.
One difficulty for understanding the functions for PIP2 in
endocytosis is that it interacts with a great variety of factors,
including lipid-modifying enzymes, such as PLD1 (Lisco-
vitch et al., 1994), and the actin cytoskeleton (Yin and Jan-
mey, 2003), which plays an undefined role in constitutive
receptor-mediated endocytosis (Fujimoto et al., 2000).
Overexpression of any of the three isoforms of PIP5KI leads
to reorganization of the actin cytoskeleton (Shibasaki et al.,
1997; Ishihara et al., 1998; Rozelle et al., 2000; Yamamoto
et al., 2001). In particular, overexpression of the PIP5KI 
isoform in CV-1 cells promotes formation of stress fibers,
and cells become elongated (Yamamoto et al., 2001). We
have shown that actin-disrupting drugs did not prevent the
PIP5KI-mediated increase in endocytosis of transferrin re-
ceptors; thus, the effects of PIP5KI for promoting stress fi-
bers is separate from its effect on endocytosis. Our results
suggest that one effect of PIP5KI  on constitutive endocy-
tosis is to increase the fraction of endocytic adaptors bound
to membranes that may in turn regulate the formation of
clathrin-coated pits. We observed that the proportions of
AP-2 proteins associated with membranes increased with in-
creasing PIP2 levels. Cells overexpressing PIP5KI  also had
more clathrin-coated pits at the plasma membrane. This ob-
servation suggests that the impact of increased PIP2 for in-
creasing endocytic rates was preferentially on the processes
for forming clathrin-coated pits, rather than those responsi-
ble for budding off clathrin-coated vesicles or that determine
the occupancy of transferrin receptors in coated pits.
Materials and methods
Reagents and antibodies
Alexa
®-labeled transferrin was purchased from Molecular Probes, Inc.
Lipid standards were purchased from Avanti Polar Lipids, Inc. [
32P]ortho-
phosphoric acid was purchased from NEN Life Science Products. All other
chemicals were purchased from Sigma-Aldrich unless otherwise specified.
Monoclonal anti  -adaptin was purchased from BD Biosciences, mono-
clonal anti-HA epitope tag was purchased from BAbCO, anti-myc was
purchased from Santa Cruz Biotechnology, Inc. Antibody to PIP5KI  was
purchased from Santa Cruz Biotechnology, Inc., polyclonal anti-PIP5KI 
was provided by C. Carpenter (Harvard University, Cambridge, MA), anti-
PIP5KI  was provided by Dr. P. De Camilli (Yale University, New Haven,
CT), and polyclonal anti-HA was produced in the Roth laboratory.
Transfection, adenovirus, and SV40 infections
Recombinant adenovirus expressing an HA-tagged version of mPIP5KI 
was obtained from Y. Shibasaki (University of Tokyo, Tokyo, Japan). Ad-
enoviruses expressing the myc-tagged type PIP5KI ,  -galactosidase, or
GFP were constructed using the AdEasy™ Adenoviral Vector System (Strat-
agene). A plasmid encoding the 90-kD splice variant of PIP5KI  was ob-
tained from the Kazusa DNA Research institute (KIAA0589), myc-tagged
and subcloned into pCMV5. A cDNA encoding an HA-tagged 87-kD
splice variant of mPIP5KI  (Ishihara et al., 1998) was obtained from Dr. P.
De Camilli with permission of Dr. Y. Oka (Tohoku University, Sendai, Ja-
pan), and was expressed using the plasmid vector pcDNA3.1. For all ex-
periments using adenovirus vectors, cells were infected at a multiplicity of
infection of 10. After 2 h, cells were washed and then cultured in fresh
DME containing 10% FCS for 36 h. For experiments expressing the HA
Y543 mutant, cells were infected with recombinant SV40 virus in suspen-
sion for 30 min on ice followed by culture in complete growth medium for
26 h. For experiments using transient transfection, cells were transfected
with pCMV5-PIP5KI  and pEGFP-C3 (CLONTECH Laboratories, Inc.) at a
ratio of 3 to 1, using LipofectAMINE™ according to the manufacturer’s in-
structions (Invitrogen).
RNA interference
siRNA oligonucleotides were designed according to the protocol provided
by Dharmacon Research, Inc. In brief, sequences of the type AA(N19) (N  
any nucleotide) from the ORF of the targeted mRNA were selected and
subjected to a BLAST
® search (National Center for Biotechnology Informa-
tion database) against the human genome sequence to ensure the specific-
ity of targeting. RNA oligonucleotides encoding both the sense and anti-
sense of the target were synthesized by the Center for Biomedical
Inventions (University of Texas Southwestern Medical Center at Dallas,
Dallas, TX), and annealed after a protocol from Dharmacon Research, Inc.
The siRNA sequence targeting PIP5KI  (GenBank/EMBL/DDBJ accession
no. U78575) was from position 1923–1943. The siRNA targeting PIP5KI 
(GenBank/EMBL/DDBJ accession no. NM_003558) encoded bases 1114–
1135. The oligonucleotide targeting PIP5KI  (GenBank/EMBL/DDBJ acces-
sion no. XM_047620) encoded bases 619–639. An oligonucleotide corre-
sponding to nucleotides 695–715 of the firefly luciferase (GenBank EMBL/
DDBJ accession no. U31240) was used as a negative control. On d 1,
HeLa cells were plated in 6-well plates at 30–40% confluency in antibi-
otic-free DME supplemented with 10% (vol/vol) FCS, 10 mM Hepes, and 1
mM sodium pyruvate. On d 2, siRNA was introduced into cells using Oli-
gofectAMINE
TM reagent according to the manufacturer’s instructions (Life
Technologies), with 10  l of 20  M siRNA and 4  l transfection reagent/
well. On d 4, cells were lysed and analyzed by Western blotting.
Quantitative real-time PCR
Total RNA was extracted from HeLa cells transfected with siRNAs using
the total RNA/mRNA isolation reagent RNA STAT-60™ (TEL-TEST, Inc.).
RNA samples were treated with DNase I (RNase-free; Roche), and were re-
verse-transcribed with random hexamers using SuperScript™ II RNase
H-reverse transcriptase to generate cDNA. Primer Express software (Perkin-
Elmer) was used to design primers for cyclophilin (used as internal control;
GenBank/EMBL/DDBJ accession no. XM_057194), forward TGCCATCGC-
CAAGGAGTAG, reverse TGC ACA GAC GGT CAC TCA AA; PIP5KI , for-
ward TCAAAGGCTCAACCTACAAACG, reverse TTTAAATGTGGGAA-
GAGGCTTCT; PIP5KI , forward GAAACGGTGCAATTCAATCG, reverse
TCCTGGCTAATTGAGGACACA; and PIP5KI , forward TGTCGCCTTC-
CGCTACTTC, reverse GGCTCATTGCACAGGGAGTAC. Primers were val-
idated through analysis of template titration and dissociation curves to es-
tablish both linearity of the reaction and production of a single product.
PCR assays were conducted on a sequence detection system (Prism
® 7000;
Applied Biosystems). The 20- l final reaction volume contained 50 ng re-
verse-transcribed RNA, 150 nM of each primer, and 10  l SYBR
® Green
PCR Master Mix (Applied Biosystems). PCR reactions were performed in
triplicate, and relative RNA levels were determined by the comparative Ct
method (User Bulletin No. 2; PerkinElmer).
Membrane fractionation
Cells were homogenized in 0.2 M sucrose buffered with 20 mM Hepes
(pH 7.3) by 25 strokes in a pre-chilled steel homogenizer, and were centri-
fuged at 960 g for 15 min at 4 C. The supernatant was then centrifuged at
128,000 g for 60 min at 4 C. Supernatants and pellets were separated and
stored at  80 C.
Endocytosis assays
Cells infected with adenoviruses or transfected with RNAi oligos were
rinsed and incubated in serum-free medium for 30 min to remove any re-
sidual transferrin, and then were exposed to 50  g/ml transferrin conju-
gated with Alexa
® Fluor 488 or 633 at 37 C for the times indicated. Inter-
nalization was stopped by chilling the cells on ice. External transferrin was
removed by washing with ice-cold serum-free DME and PBS, whereas
bound transferrin was removed by an acid wash in PBS at pH 5.0 followed
by a wash with PBS at pH 7.0. The fluorescence intensity of internalized
transferrin was measured by flow-cytometry using FACScan™ or FACSCali-
bur™ (Becton Dickinson) instruments, and the average intensity of 10,000
cells was recorded for each time point. Data are normalized to the increase
in mean fluorescence of cells infected with adenovirus expressing  -galac-
tosidase. We confirmed that the uptake of fluorescent transferrin was recep-
tor mediated by measuring the uptake of fluorescent transferrin in the pres-
ence of a 100-fold excess of nonfluorescent holotransferrin under the same
experimental conditions. No increase in cell-associated fluorescence wasT
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obtained in the presence of excess competing nonfluorescent transferrin.
Cell viability was measured by staining with propidium iodide.
Internalization of influenza mutant HA Y543
Endocytosis of an internalization-competent HA mutant was measured as
described previously (Lazarovits and Roth, 1988). In brief, CV1 cells were
infected with recombinant SV40 virus encoding the HA Y543 mutant. 26 h
after SV40 infection, cells were washed and 
35S-labeled with amino acids
for 30 min at 37 C. The labeling medium was then replaced with DME,
and after an additional incubation of 2 h at 37 C, the cells were exposed to
polyclonal anti-HA antibody on ice for 45 min. Antibody was removed,
cells were washed, and were then incubated at 37 C for 0, 2, 4, and 8 min.
Cells were then returned to ice, treated with 100  g/ml trypsin for 45 min,
and lysed in the presence of 200  g/ml soybean trypsin inhibitor and a
cocktail of protease inhibitors. The HA protein bound to antibody was im-
munoprecipitated with protein A–Sepharose and was resolved by SDS-
PAGE. The internalized HA was calculated as the fraction that became re-
sistant to trypsin cleavage and was expressed as percentage of total HA.
PIP2 analysis
Cells were labeled with 40  Ci/ml [
32P]orthophosphoric acid for 4 h in
phosphate-free DME plus 0.5% FBS. Lipids were extracted from the cells
with a 4:10:5 mixture of CHCl3:CH3OH:1N HCl and were resolved by
TLC, visualized by autoradiography, and quantified by densitometry. Lipid
standards (Avanti Polar Lipids, Inc.) were detected by iodine vapors.
Fluorescence microscopy
Cells on coverslips were washed with PBS and fixed in 3.7% PFA for 15
min. The fixative was removed and cells were washed with DME and per-
meabilized with 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% gelatin, 5
mM EDTA, 0.02% NaN3, 0.05% NP-40, and 0.05% Triton X-100. Non-
specific binding sites were blocked with PBS containing 1% BSA before in-
cubating samples with primary and secondary antibodies for 1 h at RT.
Coverslips were mounted on glass slides with Aqua-Polymount (Poly-
sciences) and visualized with a microscope (Axioplan; Carl Zeiss MicroIm-
aging, Inc.) fitted with a confocal scanning head (MRC600; Bio-Rad Labo-
ratories) and a Kr/Ar laser (Bio-Rad Laboratories) or with a confocal
microscope (model 510; Carl Zeiss MicroImaging, Inc.).
EM
Control and infected cells were processed for EM following standard pro-
cedures using osmium tetroxide and lead citrate for staining. Clathrin-
coated pits were visualized and counted at a magnification of 70,000 in an
electron microscope (model 1200EX; JEOL USA, Inc.). Digital images of
each cell were stored for analysis, and the length of plasma membrane on
which coated pits were counted was quantified using Image J 1.27z soft-
ware (National Institutes of Health, Bethesda, MD).
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